Covid-19: Pfizer and Moderna laboratories will increase the prices of their vaccines
Doses of anti-Covid, Moderna and Pfizer vaccines.
AP - Charles Krupa
Text by: RFI Follow
2 min
According to the British newspaper
Financial Times,
pharmaceutical companies Pfizer and Moderna will increase the prices of their anti-Covid vaccines in contracts currently being negotiated with the European Union.
An increase that comes in a context of concern about the outbreak of the Delta variant.
Publicity
Read more
The price of the Pfizer vaccine is expected to rise by around 25% and that of Moderna by just over 10%,
the British daily
Financial Times
has revealed
.
For the French government, this increase is justified by the new demands on the part of the European Union.
Laboratories must adapt their vaccines to new variants and allow most of the production to take place on European territory, reacted the French Secretary of State for European Affairs, Clément Beaune.
This price hike comes as concern over the spread of the Delta variant grows.
Studies have shown that
Moderna
and Pfizer / BioNTech vaccines should remain effective against this variant.
Taking advantage of the success of their serum, the two laboratories are increasing the number of contracts and reaping significant profits.
►Also read
: The anti-Covid-19 vaccine boosts Pfizer's results
The two companies have already pocketed billions of dollars, their vaccines being highly sought after for their effectiveness against Covid-19.
This situation is denounced by Oxfam, which accuses pharmaceutical groups of taking advantage of their monopolies to artificially inflate prices.
According to an investigation by this NGO, the European Union would have paid 31 billion euros more than the cost of producing the vaccines.
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Coronavirus
Health and medicine
Economy